Clinical Trials Browser

Clear Cell Tumor

NCT05371223 2024-02-26

Nab-PIPAC

Phase 2 Unknown

38 enrolled

GastrointestinalGynecologic

Pancreatic Neoplasms, Peritoneal Neoplasms

NCT03924466 2024-02-16

VUBAR

Phase 2 Unknown

55 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Clinical Trials

PEACOCC

Nab-PIPAC

VUBAR

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

NEO

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

MITO CERV 2

MITO END-3

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Vvax

BEACON

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Evaluate the Effect of ReSpace™ Hydrogel on Reducing Rectal Radiation Dose in Radiotherapy for Cervical Cancer

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

GCR-05

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

MITO28MaNGOov4

MITO 31

MITO 35a

Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis

Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

Apollo

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

PROMPT

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

GOGER-01

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Coala-T-CBD

BOLD

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer